Julia Irwin, MD
Psychiatry · Norman, OKNPI 1306951124
Payments from drug & device makers
Across 1,159 payments — averaging $13.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Lundbeck LLC$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $6K from 25 others
What the payments were for
- Food & beverage$15,75898%
- Education$3152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 162 | $2,562 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 125 | $1,795 |
| AbbVie(2 entities) | 206 | $1,776 |
| Lundbeck LLC | 77 | $1,438 |
| Johnson & Johnson | 89 | $1,315 |
| Otsuka America Pharmaceutical, Inc. | 80 | $1,278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 60 | $951 |
| Alkermes, Inc. | 38 | $804 |
| Sunovion Pharmaceuticals Inc. | 133 | $742 |
| Neurocrine Biosciences, Inc. | 42 | $713 |
| Almatica Pharma LLC | 32 | $533 |
| Vanda Pharmaceuticals Inc. | 25 | $432 |
| Axsome Therapeutics, Inc. | 14 | $294 |
| Supernus Pharmaceuticals, Inc. | 9 | $230 |
| Avanir Pharmaceuticals, Inc. | 13 | $214 |
| Idorsia Pharmaceuticals US Inc | 10 | $192 |
| Merck | 10 | $145 |
| Eisai Inc. | 8 | $137 |
| Viiv Healthcare Company | 1 | $118 |
| Indivior Inc. | 4 | $65 |
| Ironshore Pharmaceuticals Inc. | 4 | $62 |
| Sage Therapeutics, LLC | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Corium, LLC | 2 | $32 |
| Tonix Medicines, Inc. | 2 | $32 |
| Noven Therapeutics, LLC | 2 | $30 |
| Bausch Health US, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,074 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 66 | $433,053 |
| Austedo XrDeutetrabenazine | 13 | $130,602 |
| VraylarCariprazine Hcl | 44 | $77,883 |
| CaplytaLumateperone Tosylate | 32 | $54,571 |
| FanaptIloperidone | 12 | $49,131 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $47,251 |
| Invega SustennaPaliperidone Palmitate | 12 | $37,826 |
| RexultiBrexpiprazole | 24 | $37,269 |
| Abilify MaintenaAripiprazole | 14 | $37,213 |
| SpravatoEsketamine Hcl | 12 | $24,030 |
| Aripiprazole | 188 | $13,562 |
| TrintellixVortioxetine Hydrobromide | 18 | $11,808 |
| BelsomraSuvorexant | 14 | $6,201 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 124 | $5,833 |
| Duloxetine Hcl | 262 | $5,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,562 | $563,65479 claims |
| AbbVieVraylar | $1,776 | $77,88344 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,278 | $74,48238 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $1,315 | $61,85624 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,795 | $54,57132 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $432 | $49,13112 claims |
| Alkermes, Inc.Lybalvi | $804 | $47,25131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $951 | $16,24630 claims |
| MerckBelsomra | $145 | $6,20114 claims |
| Almatica Pharma LLCSertraline Hcl | $533 | $1,905201 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Norman
- Richard HartmanNorman$15K
- Vivian HasbrookNorman$12K
- Uzma ZaidiNorman$11K
- Jack GrayNorman$9K
- Joseph RippergerNorman$6K
- Keenan SmartNorman$6K
- Louise ThurmanOklahoma City$6.2M
- Veronique SebastianOklahoma City$3.8M
- Marvin PeytonOklahoma City$3.2M
- Sarah LandTulsa$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.